Thursday, 15 October 2026European Markets

BALYO Stock Bullish Momentum With A 27% Rise In The Last 21 Sessions

Loading stream...

(vianews) - shares of balyo (cac 40: balyo.pa) jumped by a staggering 27.49% in 21 sessions from 0.5 € to 0.64 € at 16:53 est on monday, after four sequential sessions in a row of gains. cac 40 is jumping 0.78% to 7,185.56 €, following the last session's downward trend.

balyo's last close was 0.64 €, 49.05% under its 52-week high of 1.26 €.

about balyo

balyo sa designs, develops, and markets material handling robots worldwide. the company offers robotic pallet and reach trucks, tuggers, stackers, counterbalanced stackers, very narrow aisles, and autonomous mobile robots. its products are used in intelligent pallet detection, barcode scanning, inter-building transport, push button configuration, machine interface, erp interfacing, and palletizers; and wms interface and 3d camera applications. the company serves 3pl, automotive, e-commerce, and consumer goods industries. balyo sa was founded in 2004 and is headquartered in arcueil, france.

earnings per share

as for profitability, balyo has a trailing twelve months eps of -0.081 €.

more news about balyo (balyo.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com